© 2020 MJH Life Sciences™ and Urology Times. All rights reserved.
ESMO Annual Congress
Chemotherapy linked to lower risk of second testicular cancer
October 07, 2020
The risk was decreased further with each additional chemotherapy cycle a patient received.
Rucaparib pharmacokinetic analyses support use in mCRPC
October 05, 2020
Rucaparib pharmacokinetics in men with prostate cancer were comparable to those reported for women with ovarian cancer.
Dual immunotherapy regimen shows early promise in urothelial carcinoma
October 01, 2020
Dual immune checkpoint blockade with the PD-1 inhibitor tislelizumab and the PD-L1 inhibitor BGB-A333 showed clinical activity in bladder cancer.
Avelumab frontline maintenance benefit sustained across subgroups in bladder cancer
September 29, 2020
An analysis from the pivotal phase 3 JAVELIN Bladder 100 trial showed that the survival benefit observed with frontline maintenance avelumab in the overall population was sustained across several prespecified patients subgroups.
Study of molecularly-guided therapy provides precision medicine insight in mRCC
September 29, 2020
The results may help guide treatment selection with immunotherapy versus targeted agents in patients with kidney cancer.
Upfront immunotherapy regimen falls short in bladder cancer
September 28, 2020
The addition of avelumab to standard first-line gemcitabine/carboplatin did not improve outcomes in patients with metastatic urothelial carcinoma.
Nivolumab/cabozantinib combo impresses as frontline kidney cancer treatment
September 25, 2020
The combination significantly improved progression-free and overall survival compared with sunitinib in frontline renal cell carcinoma.
Ipatasertib/abiraterone regimen delays progression in mCRPC with PTEN loss
September 24, 2020
The addition of the AKT inhibitor ipatasertib to abiraterone acetate and prednisone improved radiographic progression-free survival, with overall survival data still eagerly anticipated.
Enfortumab Vedotin shows robust survival outcomes in bladder cancer
September 24, 2020
The antibody-drug conjugate enfortumab vedotin significantly improved overall survival versus chemotherapy in a phase 3 trial.
Nivolumab/ipilimumab combo’s benefits durable at 4 years for treating advanced RCC
September 23, 2020
Investigators also reported that a subgroup of patients with 1 or more target kidney lesions experienced kidney tumor reduction and other benefits from the combination treatment.